药物发现
药品
计算机科学
扎那米韦
药学
虚拟筛选
医学
药理学
生物信息学
生物
病理
传染病(医学专业)
疾病
2019年冠状病毒病(COVID-19)
作者
Tanaji T. Talele,Santosh A. Khedkar,Alan C. Rigby
标识
DOI:10.2174/156802610790232251
摘要
Drug discovery and development is an interdisciplinary, expensive and time-consuming process. Scientific advancements during the past two decades have changed the way pharmaceutical research generate novel bioactive molecules. Advances in computational techniques and in parallel hardware support have enabled in silico methods, and in particular structure-based drug design method, to speed up new target selection through the identification of hits to the optimization of lead compounds in the drug discovery process. This review is focused on the clinical status of experimental drugs that were discovered and/or optimized using computer-aided drug design. We have provided a historical account detailing the development of 12 small molecules (Captopril, Dorzolamide, Saquinavir, Zanamivir, Oseltamivir, Aliskiren, Boceprevir, Nolatrexed, TMI-005, LY-517717, Rupintrivir and NVP-AUY922) that are in clinical trial or have become approved for therapeutic use. Keywords: Molecular modeling, Structure-activity relationship, X-ray crystallography, Clinical trials, Success stories
科研通智能强力驱动
Strongly Powered by AbleSci AI